Bioxytran (BIXT) Convertible Debt (2021 - 2026)
Bioxytran (BIXT) posted Convertible Debt of $1.1 million for Q1 2026, up 3.3% sequentially from $1.1 million in Q4 2025, and up 14.17% YoY from $979799.0 in Q1 2025.
Bioxytran (BIXT) Convertible Debt (2021 - 2026) Analysis & Trends
Bioxytran has reported Convertible Debt for 6 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Convertible Debt rose 14.17% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 14.17% YoY) and the FY2025 annual result came in at $1.1 million, up 14.16% from the prior year.
- Convertible Debt improved to $1.1 million in Q1 2026 per BIXT's latest filing, from $1.1 million in the prior quarter.
- Over five years, Convertible Debt peaked at $3.8 million in Q2 2022 and troughed at $62093.0 in Q1 2024.
- A 5-year average of $1.6 million and a median of $1.1 million in 2025 frame the typical range for Convertible Debt.
- The sharpest annual moves came in 2024 and 2025: Convertible Debt plunged 97.32% in 2024, then jumped 1477.95% in 2025.
- Over 5 years, Convertible Debt stood at $2.3 million in 2022, then declined by 7.65% to $2.1 million in 2023, then plunged by 55.33% to $948642.0 in 2024, then rose by 14.16% to $1.1 million in 2025, then increased by 3.3% to $1.1 million in 2026.
- According to Business Quant data, Convertible Debt over the past three periods registered $1.1 million, $1.1 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.12 Mn |
| Dec 31, 2025 | 1.08 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Mar 31, 2025 | 979,799.00 |
| Dec 31, 2024 | 948,642.00 |
| Sep 30, 2024 | 878,352.00 |
| Jun 30, 2024 | 835,507.00 |
| Mar 31, 2024 | 62,093.00 |
| Dec 31, 2023 | 2.12 Mn |
| Sep 30, 2023 | 2.09 Mn |
| Jun 30, 2023 | 2.18 Mn |
| Mar 31, 2023 | 2.31 Mn |
| Dec 31, 2022 | 2.30 Mn |
| Sep 30, 2022 | 2.28 Mn |
| Jun 30, 2022 | 3.75 Mn |
| Dec 31, 2021 | 2.25 Mn |